🇺🇸 follicle stimulating hormone in United States

97 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Ovarian Hyperstimulation Syndrome — 23 reports (23.71%)
  2. Progesterone Increased — 12 reports (12.37%)
  3. Abortion — 10 reports (10.31%)
  4. Off Label Use — 9 reports (9.28%)
  5. Abortion Spontaneous — 8 reports (8.25%)
  6. Drug Exposure Before Pregnancy — 8 reports (8.25%)
  7. Premature Baby — 8 reports (8.25%)
  8. Drug Exposure During Pregnancy — 7 reports (7.22%)
  9. Ectopic Pregnancy — 6 reports (6.19%)
  10. Foetal Exposure During Pregnancy — 6 reports (6.19%)

Source database →

follicle stimulating hormone in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is follicle stimulating hormone approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for follicle stimulating hormone in United States?

Medical University of Vienna is the originator. The local marketing authorisation holder may differ — check the official source linked above.